Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OptimizeRx ( (OPRX) ) has issued an announcement.
On March 2, 2026, OptimizeRx amended its financing agreement to extend the maturity date by two years to October 11, 2029, lengthen the period during which a 1% premium applies, and secure flexibility to repurchase up to $10 million of stock by March 15, 2027. On March 5, 2026, the board formally authorized a share buyback of up to $10 million, to be funded from cash and executed via open-market or private transactions, underscoring confidence in the company’s balance sheet after a strong 2025, improved profitability and incremental term-loan paydown.
For the fourth quarter of 2025, OptimizeRx reported essentially flat revenue at $32.2 million but expanded gross profit and delivered record GAAP net income of $5.0 million and adjusted EBITDA of $12.0 million. For full-year 2025, revenue grew 19% to $109.4 million, GAAP net income swung to a $5.1 million profit from a $20.1 million loss, adjusted EBITDA more than doubled to $24.3 million and operating cash flow rose to $18.7 million, positioning the company as a Rule of 40 performer despite management flagging near-term demand headwinds from life sciences spending caution.
Key operating metrics for 2025 showed net revenue retention of 116%, lower revenue concentration from the top 20 pharma manufacturers at 52% of total revenue and higher revenue per employee, indicating a broader customer base and efficiency gains. Management updated 2026 guidance to revenue of $109 million to $114 million and adjusted EBITDA of $21 million to $25 million, suggesting modest growth and sustained profitability as OptimizeRx seeks to maintain Rule of 40 status amid market volatility and evolving pharma marketing dynamics.
The most recent analyst rating on (OPRX) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on OptimizeRx stock, see the OPRX Stock Forecast page.
Spark’s Take on OPRX Stock
According to Spark, TipRanks’ AI Analyst, OPRX is a Neutral.
OptimizeRx’s overall stock score is driven by strong financial performance and positive earnings call sentiment, highlighting revenue growth and strategic improvements. However, technical analysis indicates bearish momentum, and valuation metrics suggest potential overvaluation, which weigh down the overall score.
To see Spark’s full report on OPRX stock, click here.
More about OptimizeRx
OptimizeRx Corp., listed on Nasdaq as OPRX, is a healthcare technology provider that helps life sciences companies reach and engage healthcare professionals and patients. Its platform supports brand visibility, reduces prescription abandonment and improves interoperability at the point of care, with a particular focus on complex specialty medications and data-driven marketing solutions for pharmaceutical manufacturers.
Average Trading Volume: 329,016
Technical Sentiment Signal: Sell
Current Market Cap: $136.4M
For detailed information about OPRX stock, go to TipRanks’ Stock Analysis page.